Prostate cancer is usually diagnosed through a sequence of evidence rather than one test: clinical risk and PSA raise or lower suspicion, prostate MRI maps suspicious tissue, a needle biopsy obtains tissue, and a pathologist determines whether cancer is actually present. PSA, digital rectal examination (DRE) and MRI can all identify men who may need biopsy, but none of them alone proves prostate cancer. In most men, the definitive diagnosis depends on microscopic examination of prostate biopsy tissue, followed by Gleason grading and an ISUP Grade Group if adenocarcinoma is found.
A high PSA does not diagnose prostate cancer, an abnormal DRE does not diagnose prostate cancer, and a PI-RADS 5 MRI does not diagnose prostate cancer. These findings estimate probability. Biopsy pathology usually provides the definitive diagnosis. An important exception exists in selected men with overwhelming evidence of advanced malignancy—such as a malignant-feeling prostate, very high PSA and metastatic imaging—when biopsy may occasionally be omitted if tissue confirmation would not alter treatment because of major comorbidity or limited therapeutic options.
01How Does Suspicion of Prostate Cancer Begin?
Most early prostate cancers are not found because of symptoms
Localized prostate cancer is commonly asymptomatic.
A man can therefore enter the diagnostic pathway because of:
- an elevated PSA;
- a rising or otherwise concerning PSA pattern;
- an abnormal digital rectal examination;
- a strong family history;
- a pathogenic inherited variant such as BRCA2;
- an incidental prostate abnormality;
- or symptoms suggesting more advanced disease.
The distinction between symptomatic and asymptomatic disease matters because urinary symptoms alone are not specific for cancer.
For example, weak urinary flow is much more often related to benign prostate enlargement than to localized prostate cancer.
What does PSA contribute?
Prostate-specific antigen is a protein produced by prostate epithelial cells.
Cancer can increase the amount entering the bloodstream, but PSA is prostate-specific rather than cancer-specific.
PSA can also rise with:
- benign prostate enlargement;
- prostatitis;
- urinary retention;
- recent manipulation of the prostate or urinary tract;
- and some temporary physiological circumstances.
That is why clinicians interpret PSA as a risk signal rather than as a positive/negative cancer test.
The biomarker itself is explained in detail in PSA Testing.
Is there one PSA level that means cancer?
No.
Cancer can occur below commonly used PSA thresholds, and benign disease can produce PSA values above them.
Clinical interpretation depends on:
- the absolute PSA;
- age;
- previous PSA results;
- prostate size;
- family history;
- genetic risk;
- DRE findings;
- and subsequent MRI findings.
Why is an unexpected PSA sometimes repeated before MRI or biopsy?
PSA has biological variability.
Current EAU guidance recommends initially repeating PSA in asymptomatic men with a newly measured PSA between approximately 3 and 10 ng/mL before automatically moving to further investigation.
The goal is to determine whether the elevation persists rather than basing an invasive diagnostic pathway on one potentially transient measurement.
What does digital rectal examination add?
During DRE, a clinician palpates the posterior surface of the prostate through the rectal wall.
Concerning findings can include:
- hardness;
- nodularity;
- marked asymmetry;
- loss of a normal contour;
- or fixation suggesting disease beyond the gland.
EAU evidence indicates that approximately 18% of prostate cancers can be detected through a suspicious DRE irrespective of PSA in historical clinical datasets.
When PSA is 4 ng/mL or lower, the positive predictive value of a suspicious DRE has been reported at approximately 5% to 30%.
Those figures show that DRE can add information—but also why DRE does not establish a diagnosis.
What does PSA density mean?
PSA density adjusts the PSA for prostate size:
PSA density = serum PSA ÷ prostate volume.
For example, a PSA of 6 ng/mL arising from a 100 mL benign prostate carries a different context from the same PSA arising from a 30 mL prostate.
MRI is particularly useful here because it can provide a prostate-volume estimate that allows PSA density to be calculated.
Clinical interpretation: PSA and DRE answer “How suspicious is this prostate?” They do not answer “Is cancer present?” The diagnostic pathway moves forward only when the combined probability is high enough to justify imaging or tissue sampling.
02What Does Prostate MRI Add Before Biopsy?
MRI turns an invisible suspicion into an anatomical target
Modern prostate MRI changed diagnosis because clinicians no longer have to sample the gland blindly in many biopsy-naïve patients.
Current EAU guidance strongly recommends prostate MRI before biopsy in men with suspected organ-confined prostate cancer.
MRI can help answer several questions at once:
- Is there a suspicious lesion?
- Where is it located?
- How large is it?
- Is it in the peripheral or transition zone?
- Is there evidence suggesting extension beyond the prostate?
- What is the prostate volume?
- Where should targeted biopsy cores be taken?
What sequences does prostate MRI use?
A multiparametric prostate MRI commonly combines:
- T2-weighted imaging for detailed prostate anatomy;
- diffusion-weighted imaging (DWI) to detect restricted water movement associated with densely cellular tissue;
- apparent diffusion coefficient (ADC) maps to quantify diffusion behavior;
- and dynamic contrast enhancement (DCE) to assess early contrast uptake when contrast-enhanced MRI is used.
High-quality biparametric MRI without contrast can also be effective in appropriately designed pathways and experienced centers.
What is PI-RADS?
PI-RADS—the Prostate Imaging Reporting and Data System—standardizes how suspicious prostate MRI findings are described.
The scale runs from 1 to 5:
- PI-RADS 1: clinically significant cancer is highly unlikely;
- PI-RADS 2: unlikely;
- PI-RADS 3: equivocal;
- PI-RADS 4: likely;
- PI-RADS 5: highly likely.
PI-RADS estimates imaging suspicion. It is not a histological diagnosis.
How strongly does PI-RADS correlate with clinically significant cancer?
In the evidence summarized by the EAU for PI-RADS version 2.1, pooled patient-level detection rates for ISUP Grade Group 2 or higher cancer were approximately:
- 6% for PI-RADS 1;
- 6% for PI-RADS 2;
- 20% for PI-RADS 3;
- 55% for PI-RADS 4;
- and 83% for PI-RADS 5.
These values should not be read as universal personal probabilities.
They are positive predictive values from study populations and therefore change according to:
- the prevalence of cancer in the population;
- PSA density;
- family history;
- radiologist experience;
- MRI quality;
- and biopsy technique.
Can a negative MRI rule out prostate cancer?
No.
A negative MRI meaningfully lowers risk, but MRI can miss clinically significant cancer.
EAU evidence summarizes a pooled negative predictive value of approximately 84% for ISUP Grade Group 2 or higher cancer across mixed diagnostic populations.
When PSA density is below 0.15 ng/mL/cc, the negative predictive value rises to about 90% in pooled data.
But when MRI is negative and PSA density remains above approximately 0.15–0.20 ng/mL/cc, the reported risk of Grade Group 2 or higher cancer can still reach approximately 27% to 40% in selected cohorts.
When can biopsy sometimes be avoided after MRI?
Current EAU guidance allows risk-adapted biopsy avoidance in selected low-risk settings.
For example:
- when MRI is negative—PI-RADS 1 or 2—and clinical suspicion is low, including PSA density below approximately 0.20 ng/mL/cc and no family history, PSA monitoring may be offered instead of immediate biopsy;
- when MRI is PI-RADS 3 and suspicion is very low, including PSA density below approximately 0.10 ng/mL/cc and no family history, biopsy may also sometimes be deferred.
These are not universal rules. They are examples of how MRI and clinical probability are combined.
Can a PI-RADS 5 lesion still be benign?
Yes.
Although PI-RADS 5 carries a high probability of clinically significant cancer, non-cancer conditions can occasionally mimic malignancy, including:
- focal prostatitis;
- granulomatous inflammation;
- stromal or glandular BPH nodules;
- post-biopsy change;
- and technical or interpretive artifacts.
This is why even highly suspicious MRI findings usually proceed to targeted tissue sampling rather than being labeled cancer from imaging alone.
Negative MRI does not equal “no cancer,” and positive MRI does not equal “cancer confirmed.” MRI changes the probability and guides where to sample. PSA density, family history, DRE and prior biopsy information remain important when deciding whether a negative or equivocal scan is reassuring enough to avoid biopsy.
03How Does Prostate Biopsy Confirm or Exclude Cancer?
Biopsy obtains the tissue that imaging cannot provide
A prostate biopsy removes narrow cores of tissue with a hollow needle.
Those cores are fixed, processed, stained and examined under a microscope.
The purpose is not simply to ask whether a suspicious lesion exists.
It is to determine:
- whether malignant prostate cells are present;
- what type of cancer is present;
- how abnormal the architecture looks;
- how much cancer occupies each sampled core;
- and whether adverse pathological patterns are present.
What is an MRI-targeted biopsy?
When MRI shows a suspicious lesion, a urologist can direct biopsy needles toward the MRI-defined target.
Targeting can be performed using:
- cognitive targeting—the operator mentally matches the MRI location to real-time ultrasound;
- MRI-ultrasound software fusion—software overlays MRI information onto ultrasound;
- or in-bore MRI biopsy—the needle is guided while the patient remains within the MRI environment.
Current evidence has not established one of these targeting techniques as universally superior in every setting. Operator experience and image quality remain important.
Why are extra cores sometimes taken around the MRI lesion?
A needle can miss the highest-grade part of a tumor even when the target is visible.
Current EAU guidance therefore recommends combining targeted biopsy with perilesional sampling when MRI shows a clearly positive lesion such as PI-RADS 4 or 5.
Perilesional cores sample tissue immediately around the target and can capture clinically significant cancer missed by the exact target needle trajectory.
Is systematic biopsy still used?
Yes, depending on the diagnostic situation.
Systematic cores sample predefined prostate regions rather than one MRI lesion.
They remain useful when:
- MRI is negative but clinical suspicion remains high;
- PSA density is high;
- prior biopsy and MRI results conflict;
- or the chosen biopsy strategy requires broader gland sampling.
However, MRI-directed approaches increasingly allow clinicians to reduce unnecessary cores and reduce detection of very-low-risk disease while maintaining sensitivity for clinically significant cancer.
Transperineal or transrectal biopsy?
Biopsy needles can reach the prostate by two main routes:
- transperineal: through the skin between the scrotum and anus;
- transrectal: through the rectal wall.
Both can detect prostate cancer and both can be performed with local anesthesia.
Current EAU guidance strongly prefers the transperineal approach because of its lower risk of infectious complications and its advantages for antibiotic stewardship.
How much lower is the infection risk?
A 2026 meta-analysis of contemporary randomized trials found that transperineal biopsy had approximately 62% lower odds of infectious complications than transrectal biopsy, while clinically significant cancer detection remained similar.
Another 2026 randomized-trial meta-analysis found substantially lower odds of hospital admission for infection after the transperineal route.
These data support the increasing shift toward transperineal biopsy.
Does biopsy hurt?
Modern prostate biopsy can usually be performed with local anesthesia.
Transperineal biopsy may produce more procedural discomfort in some techniques because multiple skin punctures or wider perineal anesthetic blocks may be required, although contemporary freehand and local-anesthetic approaches have improved tolerability substantially.
What are the main biopsy risks?
Potential complications include:
- blood in urine;
- blood in semen;
- temporary perineal or rectal discomfort;
- difficulty urinating or acute urinary retention;
- infection;
- and, rarely, serious infection or sepsis.
The infectious risk is one reason the route of biopsy now matters clinically.
Can a negative biopsy miss cancer?
Yes.
A biopsy samples a small fraction of the prostate.
A negative biopsy therefore means cancer was not identified in the tissue sampled, not that cancer is impossible anywhere in the gland.
Persistent concern after a negative biopsy may be driven by:
- continued PSA elevation;
- high PSA density;
- a persistent PI-RADS 4 or 5 lesion;
- concerning DRE;
- or strong inherited risk.
In those circumstances, continued surveillance or repeat targeted biopsy may be appropriate.
Biopsy solves the tissue question, but sampling error still exists. MRI targeting and perilesional sampling reduce that problem, yet no needle strategy can physically examine every prostate cell. Discordant PSA, MRI and pathology results should therefore be interpreted together rather than forcing one test to overrule all others.
04What Does the Pathologist Look for After a Prostate Biopsy?
Pathology establishes whether prostate adenocarcinoma is present
Most prostate cancers are acinar adenocarcinomas.
Under the microscope, the pathologist evaluates whether prostate glands retain normal architecture or show malignant features such as:
- abnormal infiltrative gland formation;
- loss of the normal basal-cell layer;
- nuclear enlargement and nucleoli;
- abnormal gland fusion;
- poorly formed glands;
- cribriform architecture;
- or solid tumor growth.
Special immunohistochemical stains can be used when routine microscopic appearance is equivocal.
What is the Gleason score?
Gleason grading describes the architectural pattern of prostate adenocarcinoma.
In contemporary needle-biopsy practice, malignant patterns are mainly assigned as:
- pattern 3: separate, relatively well-formed malignant glands;
- pattern 4: fused, poorly formed or cribriform malignant glands;
- pattern 5: essentially no gland formation, solid sheets, cords or individual cells, with some highly aggressive morphological patterns.
The two dominant patterns are added together.
For example:
- 3 + 3 = Gleason 6;
- 3 + 4 = Gleason 7;
- 4 + 3 = Gleason 7;
- 4 + 4 = Gleason 8;
- 4 + 5 = Gleason 9.
Why are Gleason 3+4 and 4+3 not equivalent?
The first number represents the dominant pattern.
Therefore:
- Gleason 3+4 contains more pattern 3 and less pattern 4;
- Gleason 4+3 contains more pattern 4.
Because pattern 4 carries more aggressive architecture, 4+3 disease generally represents a higher-risk pathological state than 3+4 disease despite both adding to 7.
What is ISUP Grade Group?
The Grade Group system translates Gleason scores into five clinically clearer categories:
| Grade Group | Typical Gleason score | Pathological meaning |
|---|---|---|
| Grade Group 1 | 3 + 3 = 6 | Lowest contemporary prostate adenocarcinoma grade used on biopsy. |
| Grade Group 2 | 3 + 4 = 7 | Predominantly pattern 3 with a smaller pattern 4 component. |
| Grade Group 3 | 4 + 3 = 7 | Predominantly pattern 4; biologically more concerning than 3+4. |
| Grade Group 4 | Gleason score 8 | High-grade cancer, including patterns such as 4+4, 3+5 or 5+3. |
| Grade Group 5 | Gleason 9–10 | Highest Grade Group, with extensive pattern 5 and/or very high-grade architecture. |
What else should a biopsy pathology report describe?
Current EAU pathology standards recommend reporting clinically important details beyond the Grade Group.
These can include:
- type of carcinoma;
- Gleason primary and secondary patterns;
- ISUP Grade Group;
- percentage of Gleason pattern 4 in Gleason 7 tumors;
- number of positive cores;
- amount of cancer in each core;
- grade within MRI-targeted lesions;
- presence or absence of intraductal carcinoma;
- presence or absence of invasive cribriform architecture;
- and, when seen, extraprostatic extension or lymphovascular invasion.
Does the biopsy Grade Group tell the stage?
No.
Grade and stage answer different questions.
Grade describes the microscopic aggressiveness of the cancer.
Stage describes where the cancer is anatomically:
- confined to the prostate;
- extending outside the gland;
- involving seminal vesicles;
- involving lymph nodes;
- or metastatic to distant sites such as bone.
Staging can require:
- DRE;
- MRI;
- PSMA PET/CT;
- CT;
- bone imaging;
- and other investigations depending on cancer risk.
What does “clinically significant prostate cancer” mean?
In contemporary diagnostic research, clinically significant prostate cancer is commonly defined as ISUP Grade Group 2 or higher.
That threshold is useful for evaluating MRI and biopsy strategies because the clinical goal is not simply to find every microscopic prostate cancer.
The goal is to preferentially detect cancers likely to matter while reducing unnecessary diagnosis of very-low-risk disease.
What if the biopsy shows Grade Group 1?
Grade Group 1 is still prostate adenocarcinoma.
However, many localized Grade Group 1 cancers have low biological risk and may be managed with active surveillance rather than immediate surgery or radiation.
The actual decision depends on:
- PSA and PSA density;
- number and extent of positive cores;
- MRI findings;
- clinical stage;
- age and health;
- genetic risk;
- and patient preferences.
Can the biopsy underestimate the true grade?
Yes.
A biopsy samples only part of the cancer.
A prostate removed later at surgery may occasionally contain:
- more pattern 4;
- a higher Grade Group;
- a larger tumor;
- or disease extending farther than predicted from biopsy alone.
MRI-targeted and regional sampling have improved accuracy, but sampling error has not disappeared.
Pathology is the diagnostic anchor. PSA estimates probability, MRI shows suspicious anatomy and biopsy obtains the sample. Once malignant glands are identified microscopically, the diagnosis becomes a tissue diagnosis and the next questions shift toward grade, stage, risk classification and treatment strategy.
→What Each Prostate Cancer Diagnostic Test Can—and Cannot—Tell You
| Test | What it contributes | What it cannot prove by itself |
|---|---|---|
| PSA blood test | Estimates prostate-cancer probability and helps determine whether further evaluation is justified. | Cannot distinguish cancer from all benign causes of PSA elevation. |
| Repeat PSA | Helps confirm whether a new elevation persists. | Cannot exclude cancer simply because PSA falls. |
| Digital rectal examination | Can identify nodularity, hardness, asymmetry or clinically advanced local disease. | Cannot reliably detect all prostate cancers or determine histological grade. |
| PSA density | Adjusts PSA for prostate volume and refines risk before or after MRI. | Is not a standalone biopsy diagnosis. |
| Prostate MRI | Localizes suspicious lesions, estimates prostate volume and guides targeted biopsy. | Cannot reliably distinguish every cancer from benign mimics. |
| PI-RADS score | Standardizes MRI suspicion from 1 to 5. | Does not equal Grade Group and does not confirm cancer. |
| MRI-targeted biopsy | Samples the lesion most suspicious on MRI. | Can still miss cancer because of targeting or sampling error. |
| Perilesional biopsy | Samples tissue immediately around a suspicious MRI target. | Does not completely sample the entire gland. |
| Systematic biopsy | Samples predefined prostate regions and can detect MRI-invisible disease. | Can miss small tumors and can detect clinically insignificant cancer. |
| Biopsy pathology | Usually establishes the diagnosis and provides Gleason score, Grade Group and tumor extent. | Does not by itself fully establish whole-body stage. |
| PSMA PET/CT or staging imaging | Assesses spread in appropriate newly diagnosed higher-risk disease. | Does not normally replace prostate tissue pathology as the primary diagnostic standard. |
?Common Questions About Prostate Cancer Diagnosis
| Question | Practical answer |
|---|---|
| What test confirms prostate cancer? | In most men, prostate biopsy with histopathological examination confirms the diagnosis. |
| Can PSA alone diagnose prostate cancer? | No. PSA raises or lowers suspicion but is not cancer-specific. |
| Can prostate cancer occur with a “normal” PSA? | Yes. No PSA value completely excludes prostate cancer. |
| Does high PSA always mean cancer? | No. BPH, prostatitis, urinary retention and other prostate conditions can raise PSA. |
| Why repeat PSA before biopsy? | A new PSA elevation can be temporary, so repeat testing can prevent unnecessary investigation based on one variable measurement. |
| Can DRE detect prostate cancer? | It can identify suspicious nodules or locally advanced disease, but it cannot reliably diagnose cancer by itself. |
| What is PSA density? | PSA divided by prostate volume. It helps distinguish a PSA value arising from a very large prostate from the same PSA in a smaller gland. |
| Do I need MRI before prostate biopsy? | Current EAU guidance strongly recommends MRI before biopsy when organ-confined prostate cancer is suspected. |
| What does PI-RADS 3 mean? | It means the MRI finding is equivocal for clinically significant prostate cancer. |
| What does PI-RADS 4 mean? | Clinically significant cancer is considered likely, so targeted biopsy is commonly considered. |
| What does PI-RADS 5 mean? | Clinically significant cancer is highly likely, but pathology is still usually needed for confirmation. |
| Can PI-RADS 5 be benign? | Yes. Inflammation, BPH nodules and other abnormalities can occasionally mimic cancer. |
| Can a negative MRI miss prostate cancer? | Yes. Negative MRI lowers risk but does not reduce it to zero. |
| What makes a negative MRI less reassuring? | High PSA density, strong family history, abnormal DRE, genetic risk or persistent PSA concern. |
| Can biopsy be avoided after a negative MRI? | Sometimes, when overall clinical suspicion is low. The decision uses PSA density, family history and other risk information. |
| What is an MRI fusion biopsy? | Software aligns the MRI lesion with real-time ultrasound so the urologist can direct biopsy needles toward the MRI target. |
| What is a transperineal biopsy? | A prostate biopsy in which needles pass through the perineal skin rather than through the rectal wall. |
| Why is transperineal biopsy increasingly preferred? | It offers similar cancer detection with lower infectious risk and reduced reliance on antibiotic prophylaxis. |
| Can a negative biopsy miss cancer? | Yes. Persistent high-risk findings can justify continued monitoring or repeat biopsy. |
| What is Gleason 3+4? | Gleason score 7 with predominantly pattern 3 and a smaller pattern 4 component; this corresponds to Grade Group 2. |
| What is Gleason 4+3? | Gleason score 7 with predominantly pattern 4; this corresponds to Grade Group 3 and generally carries greater biological risk than 3+4. |
| What is Grade Group 1? | Gleason 3+3=6 prostate adenocarcinoma, the lowest Grade Group used in contemporary prostate-cancer grading. |
| Does Grade Group tell me the cancer stage? | No. Grade describes microscopic aggressiveness; stage describes anatomical extent and spread. |
| What is clinically significant prostate cancer? | Diagnostic studies commonly define it as ISUP Grade Group 2 or higher. |
| Does every diagnosed prostate cancer need immediate treatment? | No. Some localized low-risk cancers are managed with active surveillance rather than immediate surgery or radiation. |
| Can prostate cancer ever be diagnosed without prostate biopsy? | Rarely. In selected men with overwhelming evidence of advanced malignancy and circumstances in which tissue confirmation would not change management, biopsy may occasionally be omitted. |
ΣThe Diagnostic Process in One Clinical Sequence
- Risk or an abnormal prostate signal appears. This may be PSA elevation, suspicious DRE, inherited risk, family history or symptoms.
- The PSA result is interpreted rather than treated as a cancer diagnosis. Unexpected results may be repeated and benign causes considered.
- Prostate size and PSA density refine the probability. The same PSA can carry different implications in a 30 mL versus a 100 mL prostate.
- MRI maps suspicious prostate tissue. PI-RADS describes imaging suspicion from 1 to 5.
- Negative MRI is interpreted with the clinical context. Low PSA density and no major risk factors may support monitoring rather than immediate biopsy.
- Positive or persistently concerning findings lead to biopsy. MRI targets guide tissue sampling.
- Transperineal biopsy is increasingly preferred. Current EAU guidance recommends it because of lower infectious risk and better antibiotic stewardship.
- Targeted and regional/perilesional samples reduce sampling error. Systematic sampling remains useful in selected situations.
- Pathology establishes whether malignant glands are present. Most prostate cancers are acinar adenocarcinomas.
- The pathologist assigns Gleason patterns and Grade Group. Grade Group 1 through 5 summarizes progressively more adverse cancer architecture.
- The amount and pattern of cancer are reported. Positive-core count, tumor extent, percentage pattern 4, cribriform morphology and intraductal carcinoma can matter.
- Diagnosis then becomes risk classification and staging. PSA, Grade Group, MRI, clinical stage and appropriate staging imaging determine what the confirmed cancer means clinically.
Clinical bottom line: prostate cancer diagnosis is an evidence chain rather than a single-test event. PSA and DRE create suspicion, MRI localizes and refines that suspicion, biopsy obtains the tissue, and pathology usually establishes the diagnosis. A negative MRI can reduce the need for biopsy in carefully selected low-risk men, while a suspicious MRI still needs tissue confirmation in most cases. Once adenocarcinoma is identified, Gleason score and Grade Group become central to determining how biologically important the cancer may be.
Medical disclaimer: This article provides general medical education and cannot determine whether an individual needs PSA testing, MRI or prostate biopsy. Decisions depend on age, life expectancy, PSA history, prostate volume, family history, genetic risk, examination findings and local expertise. A suspicious PSA or MRI is not itself a cancer diagnosis, and a negative test does not always exclude clinically significant disease.
Continue through the diagnostic pathway: return to the Prostate Cancer hub for the complete disease pathway. For the blood biomarker that commonly starts diagnostic evaluation, see PSA Testing. For the preceding risk discussion, see Testosterone, TRT and Prostate Cancer Risk. The next guide examines prostate MRI in detail, including multiparametric sequences, PI-RADS scoring, lesion interpretation and what a negative MRI actually means.
Evidence Sources
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: PSA, DRE, PSA density, MRI, PI-RADS, biopsy strategy, pathology and transperineal biopsy recommendations.
- National Cancer Institute — Prostate-Specific Antigen Test: interpretation, limitations and non-cancer causes of elevated PSA.
- National Cancer Institute — Prostate Cancer Treatment (Patient Version): biopsy, Gleason score and Grade Group.
- American Urological Association / Society of Urologic Oncology — Early Detection of Prostate Cancer: MRI, biopsy and risk-directed diagnostic evaluation.
- American College of Radiology — PI-RADS: standardized acquisition and interpretation of prostate MRI.
- Marra G, et al. Transperineal Versus Transrectal Biopsy for Prostate Cancer Diagnosis: Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology Oncology. 2026.
- Stangl FP, et al. Infectious Complications After Transrectal Versus Transperineal Prostate Biopsy: Systematic Review and Meta-analysis. European Urology Focus. 2026.
